The Relationship of miRNA-155 Expression with B-cell activating factor (BAFF) Level in Systemic lupus erythematosus patients
DOI:
https://doi.org/10.46649/vw428j87Keywords:
Autoimmune disease, Systemic lupus erythematosus, BAFF, MicroRNA-155Abstract
Background: The multisystemic autoimmune illness known as systemic lupus erythematosus (SLE) is typified by autoantibodies against nuclear antigens. miRNA expression upregulation and its function in the immune system. Changes in miRNA-155 expression in B cells, which also contribute to immune system hyperactivity, are linked to the start or remission of SLE.
Objectives: Assessing the amount of miRNA-155 and its association with the cytokine (BAFF) in both healthy controls and SLE patients in order to ascertain their possible application as biomarkers for the diagnosis of the illness.
Methods: In this study, 150 individuals (10 men and 140 females) were split into two groups: 50 healthy controls and 100 SLE patients. Participants ranged in age from 12 to 60 years. Patients were recruited from the Rheumatology Consulting Clinic and the Biological Injection Unit at Marjan Teaching Hospital in Babil Governorate, Iraq.
Results: SLE patients had substantially higher levels of miRNA-155 expression (fold change = 3.36) than the control group (fold change = 0.95), (P = 0.001). Using the enzyme-linked immunosorbent assay (ELISA), BAFF concentrations in SLE patients were substantially higher (0.62 µg/L) than in the control group (0.38 µg/L) (P = 0.001).
Conclusions: MicroRNA-155 and BAFF have a somewhat favorable connection that advances SLE. Patients with SLE had greater levels of BAFF and miRNA-155 expression, which can be utilized as a predictive biomarker for the activity of the illness. Finally, these results revealed that miRNA-155 and BAFF can be a good diagnostic biomarker for SLE diagnosis.
Published
Issue
Section
License
The Corresponding Author, with the consent of all coauthors, hereby transfers to the FJHMS the copyright ownership in referenced Article, including all versions in any format now known or the hereafter developed. If the Article is not accepted by FJHMS or withdrawn prior to acceptance, this transfer will be null and void.
In order for your article to be distributed as widely as possible your grant the FJHMS an exclusive right to:
- Publish, reproduce, distribute, display, and store the Article in all forms, formats, and media known or later developed (including without limitation in print, digital, and electronic form) throughout the world;
- Translate the Article into other languages, create adaptations, summaries or extracts of the Article or other derivative works based on the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, and derivative works;
- License others to do any or all of the above
All accepted Articles become the property of FJHMS and may not be published elsewhere without written permission of the FJHMS
